http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010285146-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a426b068545671a1d02fed270b5c980
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-3472
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-3486
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-3679
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01D15-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J20-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16
filingDate 2008-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_129861a134b0c40a555cd0d8ff69f44c
publicationDate 2010-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2010285146-A1
titleOfInvention Peptides and methods for the treatment of systemic lupus erythematosus
abstract A method is disclosed for treating systemic lupus erythematosus in a mammalian subject, comprising administering to said subject an effective dose of at least one laminin peptide, or an analog or a derivative thereof. In one exemplary embodiment, the laminin peptide is selected from the group consisting of R38 (SEQ. ID. NO. 1), and claimed R38 analogs and derivatives thereof including 5200 (SEQ. ID. NO. 10), 5104 (SEQ. ID. NO. 15), 5105 (SEQ. ID. NO. 16), 5106 (SEQ. ID. NO. 17), 5107 (SEQ. ID. NO. 18), 5108 (SEQ. ID. NO. 19), 5109 (SEQ. ID. NO. 20), 5110 (SEQ. ID. NO. 21). The laminin peptides of the present invention may be prepared by known chemical synthetic methods or by biotechnological methods. The invention also provides assays useful for the diagnosis of and following pathological activity course of systemic lupus erythematosus in patients suffering therefrom. In addition, the subject invention concerns a method of treating systemic lupus erythematosus in a subject comprising the extracorporeal removal of lupus antibodies from the subject's plasma and returning the plasma to the subject. In an additional aspect, the invention provides method of reducing anti-R38 antibody levels in a patient's plasma.
priorityDate 2007-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002054872-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394420
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127719861
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57199466
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226402238
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP83456
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP21948
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID588
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP86348
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP19147
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO60109
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00634
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID34068
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ05700
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID39118
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID232
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP81800
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393977
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395683
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1010633
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4914
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ05205
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID1010633
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID38723
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID43946
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7618

Total number of triples: 45.